BioHarvest Sciences (BHST) AI Stock Analysis

• Market Cap: $139.70M
• Dividend Yield: N/A
• Average Volume (3M): 109.63K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.45
• Revenue Growth: 57.83%
• EPS Growth: 40.94%
• Country: US
• Employees: 87
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Agricultural Inputs
• EPS (TTM): -0.24
• Shares Outstanding: 19,593,267
• 10 Day Avg. Volume: 113,678
• 30 Day Avg. Volume: 109,634
• PEG Ratio: 0.55
• Price to Book (P/B): 75.25
• Price to Sales (P/S): 3.97
• P/FCF Ratio: -10.51
• Enterprise Value/Market Cap: 0.97
• Enterprise Value/Revenue: 4.49
• Enterprise Value/Gross Profit: 7.74
• Enterprise Value/Ebitda: -23.28
• 1Y Price Target: $14.50
• Price Target Upside: 28.55% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: $7.00 ▼(-37.94% Downside)

BioHarvest Sciences faces significant financial challenges, with high leverage and negative equity impacting its financial stability. Despite this, the company shows potential for growth through strategic initiatives and product launches, as highlighted in the earnings call. Technical indicators suggest bearish momentum, and the valuation remains unattractive due to ongoing losses.

Positive Factors

Revenue Growth

Strong revenue growth indicates successful market penetration and product acceptance, supporting long-term business expansion.

Gross Margin Expansion

Improved gross margins reflect operational efficiencies and cost management, enhancing profitability potential over time.

Strategic Partnerships

Strategic partnerships expand product offerings and market reach, leveraging technology for sustainable growth in new segments.

Negative Factors

High Leverage

High leverage poses financial risk, limiting flexibility and increasing vulnerability to economic fluctuations, impacting long-term stability.

Negative Cash Flow

Negative cash flow challenges sustainability, requiring careful management to avoid liquidity issues and support ongoing operations.

Increased Operating Expenses

Rising operating expenses can erode profitability, necessitating strategic cost controls to maintain financial health and growth.

BioHarvest Sciences Business Overview & Revenue Model

Company Description

BioHarvest Sciences (BHST) is a biotechnology company focused on the development and commercialization of innovative plant-based products, primarily in the health and wellness sectors. The company utilizes its proprietary BioHarvest technology to cultivate high-value plant cell cultures that produce bioactive compounds and nutraceuticals. Its core products include specialized compounds for dietary supplements, cosmetics, and functional foods, aimed at improving health outcomes and enhancing consumer wellness.

How the Company Makes Money

BioHarvest Sciences generates revenue through the sale of its plant-based products and compounds to various sectors, including dietary supplements and cosmetics. The company leverages its proprietary technology to create high-quality, scalable products that meet the growing demand for natural and sustainable health solutions. Key revenue streams include direct sales to manufacturers and retailers, licensing agreements for its technology, and potential partnerships with larger firms in the health and wellness industry. Additionally, BioHarvest may benefit from strategic collaborations and joint ventures that enhance its market reach and product offerings.

BioHarvest Sciences Financial Statement Overview

Summary

BioHarvest Sciences is experiencing revenue growth, but struggles with profitability and financial stability. High leverage and negative equity raise concerns about long-term sustainability. Despite operational efficiencies, persistent losses and cash flow issues weaken the overall financial health.

Income Statement

BioHarvest Sciences shows a positive revenue growth rate of 8.99% TTM, indicating potential market expansion. However, the company struggles with profitability, evidenced by negative net profit margins (-39.96%) and EBIT margins (-24.26%). The gross profit margin is relatively healthy at 58.02%, suggesting efficient production processes, but the overall financial health is hindered by significant net losses.

Balance Sheet

The balance sheet reveals a concerning financial structure with a negative stockholders' equity and a high debt-to-equity ratio of -4.99 TTM, indicating financial instability and potential solvency issues. The return on equity is significantly negative (-130.35%), reflecting the company's inability to generate profits from shareholders' investments.

Cash Flow

Cash flow analysis shows a negative operating cash flow and free cash flow, with a slight decline in free cash flow growth (-6.29% TTM). The free cash flow to net income ratio is positive at 1.31, suggesting some efficiency in converting net income into free cash flow, but the overall cash flow situation remains challenging due to ongoing losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	30.17M	25.19M	12.67M	5.50M	2.10M	396.00K
Gross Profit	17.50M	13.94M	5.63M	1.22M	670.00K	138.00K
EBITDA	-5.82M	-9.72M	-9.76M	-9.13M	-8.64M	-5.77M
Net Income	-12.06M	-12.91M	-12.56M	-11.24M	-9.83M	-6.58M
Balance Sheet
Total Assets	27.80M	25.00M	15.00M	9.39M	10.21M	5.30M
Cash, Cash Equivalents and Short-Term Investments	3.73M	2.39M	5.36M	1.74M	4.12M	1.78M
Total Debt	21.09M	14.09M	22.34M	10.56M	2.66M	2.71M
Total Liabilities	32.02M	23.67M	29.86M	15.32M	7.35M	7.60M
Stockholders Equity	-4.22M	1.33M	-14.85M	-5.93M	2.85M	-2.29M
Cash Flow
Free Cash Flow	-9.21M	-9.52M	-10.00M	-10.50M	-8.43M	-4.05M
Operating Cash Flow	-7.03M	-6.68M	-8.52M	-9.24M	-6.79M	-3.88M
Investing Cash Flow	-2.14M	-3.03M	-1.47M	-1.26M	-1.64M	-173.00K
Financing Cash Flow	7.80M	6.78M	13.56M	8.14M	10.77M	4.93M

BioHarvest Sciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 11.28
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BHST, the sentiment is Negative. The current price of 11.28 is above the 20-day moving average (MA) of 9.85, above the 50-day MA of 9.69, and above the 200-day MA of 7.40, indicating a bearish trend. The MACD of -0.82 indicates Positive momentum. The RSI at 32.55 is Neutral, neither overbought nor oversold. The STOCH value of 17.52 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BHST.

BioHarvest Sciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IH	68 Neutral	$135.04M	9.28	11.71%	3.14%	-8.09%	-15.28%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
BHST	46 Neutral	$139.70M	―	-973.22%	―	57.83%	40.94%
SGMO	45 Neutral	$173.03M	―	-480.02%	―	-37.13%	40.47%
PRE	45 Neutral	$174.07M	―	-23.93%	―	159.45%	8.59%
AGEN	44 Neutral	$126.82M	―	―	―	-33.41%	81.19%
HURA	36 Underperform	$127.76M	-0.70	-287.92%	―	―	97.61%

BioHarvest Sciences Corporate Events

BioHarvest Sciences Partners with Saffron Tech for Saffron Compound Development

On October 30, 2025, BioHarvest Sciences announced a strategic CDMO agreement with Saffron Tech Ltd., aimed at developing and commercializing saffron-derived botanical compounds. This collaboration leverages BioHarvest’s Botanical Synthesis platform and Saffron Tech’s advanced cultivation methods to produce saffron compounds more sustainably and efficiently. The agreement grants Saffron Tech a 75% ownership of the developed compositions, while BioHarvest retains 25%. This partnership is expected to revolutionize saffron production by transitioning from traditional field-based cultivation to a controlled, cell-based process, addressing global supply challenges and expanding BioHarvest’s product offerings in the nutraceutical market.

BioHarvest Sciences Partners with Saffron Tech to Transform Saffron Production

On October 30, 2025, BioHarvest Sciences announced a strategic partnership with Saffron Tech to develop and commercialize saffron-derived botanical compounds using BioHarvest’s Botanical Synthesis platform. This collaboration aims to revolutionize saffron production by enabling consistent, scalable, and cost-effective production, addressing the challenges of traditional saffron cultivation. The partnership will allow BioHarvest to leverage its technology for large-scale manufacturing and marketing of saffron-based nutraceutical products. Additionally, BioHarvest shared its preliminary third-quarter 2025 results, with expected revenue of approximately $9.1 million and provided guidance for the fourth quarter, highlighting growth in its VINIA® business and CDMO services.

BioHarvest Sciences Fortifies Financial Position with $10.9 Million Warrant Exercises and Debt Conversions

On September 22, 2025, BioHarvest Sciences Inc. announced a successful series of financial transactions, including $10.9 million in warrant exercises and $3.8 million in debt conversions. These actions were aimed at strengthening the company’s financial position by reducing debt and increasing cash reserves. The transactions involved raising $5.8 million through warrant exercises, $5.1 million from new convertible notes, and converting $1.8 million of existing notes into shares. Additionally, $1.4 million of long-term debt was repaid through warrant exercises, and $0.6 million of short-term debt was settled by issuing shares. The proceeds will support capital expenditures, debt refinancing, and general working capital, positioning the company for continued growth.

BioHarvest Sciences Unveils Breakthrough in Plant-Based Exosome Production

On September 10, 2025, BioHarvest Sciences announced a significant breakthrough in its Botanical Synthesis technology by successfully producing plant-based exosomes at scale in its bioreactors. This advancement not only enhances the company’s proprietary platform but also opens new revenue streams in the cosmetics, health, and pharmaceutical industries. The plant-based exosomes, enriched with viniferin, offer superior absorption and bioavailability, making them highly desirable for therapeutic and cosmetic applications. This development positions BioHarvest as a key player in the growing exosome market, which is expected to expand significantly by 2030.

BioHarvest Sciences Files Shelf Registration for $100M Offering

On September 8, 2025, BioHarvest Sciences Inc. announced the filing and effectiveness of a shelf registration statement on Form F-3 with the U.S. Securities and Exchange Commission. This registration allows the company to offer and sell up to USD $100 million of its securities, including common shares, warrants, and units, subject to market conditions and the company’s capital needs. This strategic move positions BioHarvest to potentially enhance its financial flexibility and market presence, although it does not obligate the company to sell any specific amount of securities.

BioHarvest Sciences’ Shelf Registration Statement Goes Effective

On September 8, 2025, BioHarvest Sciences Inc. announced the effectiveness of its shelf registration statement on Form F-3 with the SEC, allowing the company to offer and sell up to USD $100 million of its securities, including common shares, warrants, and units. This strategic move provides BioHarvest with flexibility to raise capital as needed, subject to market conditions and SEC regulations, potentially strengthening its financial position and supporting its growth initiatives.

BioHarvest Sciences Updates Insider Trading Policy

On August 13, 2025, BioHarvest Sciences announced that its board of directors has adopted an amended insider trading policy. The new policy adjusts the trading window to open after the close of trading on the second full trading day following the public release of quarterly or year-end results and closes fifteen days before the due date of these results. This change aims to provide a more reasonable trading period, potentially impacting how stakeholders engage with the company’s stock.

BioHarvest Sciences Updates Insider Trading Policy to Enhance Trading Window

On August 13, 2025, BioHarvest Sciences Inc. announced the adoption of an amended insider trading policy by its board of directors. The new policy adjusts the trading window to open after the close of trading on the second full trading day following the public release of quarterly or year-end results and to close fifteen days before the due date of these results. This change is expected to provide a more reasonable trading period, potentially impacting the company’s operations by aligning trading activities with financial disclosures.